Alarming levels of multidrug-resistant tuberculosis in Ukraine: Results from the first national survey

International Journal of Tuberculosis and Lung Disease

Volumn 22, Issue 2, 2018, Pages 197-205

  Pavlenko, E ^a   Barbova, A ^a   Hovhannesyan, A ^b   Tsenilova, Z ^c   Slavuckij, A ^c   Shcherbak Verlan, B ^c   Zhurilo, A ^d   Vitek, E ^e   Skenders, G ^f   Sela, I ^f   Cabibbe, A M ^g   Cirillo, D M ^g   De Colombani, P ^h   Dara, M ^h   Dean, A ^b   Zignol, M ^b   Dadu, A ^h  

^a Ministry of Health of Ukraine   (Ukraine)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c WHO Country Office in Ukraine   (Ukraine)

^d STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^e US Agency for International Development Regional Mission for Ukraine   (Ukraine)

^f TB Supranational Reference Laboratory   (Latvia)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

Author keywords

Drug resistance; Surveillance; Tuberculosis; Ukraine

Indexed keywords

PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GROUPS BY AGE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGEN LOAD; PNCA GENE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; RURAL AREA; SEX DIFFERENCE; SOCIAL CLASS; SPUTUM ANALYSIS; SPUTUM CULTURE; TUBERCULOSIS; UKRAINE; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; QUESTIONNAIRE; SEX FACTOR; SOCIOECONOMICS; SPUTUM; YOUNG ADULT;

ADULT; AGED; ANTITUBERCULAR AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; SPUTUM; SURVEYS AND QUESTIONNAIRES; TUBERCULOSIS, MULTIDRUG-RESISTANT; UKRAINE; YOUNG ADULT;

EID: 85040770033     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.17.0254     Document Type: Review

References (25)

1. World Health Organization. Global tuberculosis report, 2017. WHO/HTM/TB/2017.23. Geneva, Switzerland: WHO, 2017.
2. Zignol M, Dara M, Dean A S, et al. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data. Drug Resist Updat 2013; 16: 108-115.
3. Dubrovina I, Miskinis K, Lyepshina S, et al. Drug-resistant tuberculosis and HIV in Ukraine: a threatening convergence of two epidemics? Int J Tuberc Lung Dis 2008; 12: 756-762.
4. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2012. Sweden, Stockholm: ECDC, 2012.
5. World Health Organization. Guidelines for surveillance of drug resistance in tuberculosis. 5th ed. WHO/TB/2015.13. Geneva, Switzerland: WHO, 2015.
6. Zignol M, Dean A S, Falzon D, et al. Twenty years of global surveillance of anti-tuberculosis drug resistance. N Engl J Med 2016; 375: 1081-1089.
7. World Health Organization. Guidelines for treatment of drugsusceptible tuberculosis and patient care. 2017 update. WHO/ HTM/TB/2017.05. Geneva, Switzerland: WHO, 2017.
8. Mulia N, Schmidt L A, Ye Y, Greenfield T K. Preventing disparities in alcohol screening and brief intervention: the need to move beyond primary care. Alcohol Clin Exp Res 2011; 35: 1557-1560.
9. Whitfield M G, Warren R M, Streicher E M, et al. Mycobacterium tuberculosis pncA polymorphisms that do not confer pyrazinamide resistance at a breakpoint concentration of 100 micrograms per milliliter in MGIT. J Clin Microbiol 2015; 53: 3633-3635.
10. Miotto P, Cabibbe A M, Feuerriegel S, et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. MBio 2014; 5: e01819-e01814.
11. Ramirez-Busby S M, Valafar F. Systematic review of mutations in pyrazinamidase associated with pyrazinamide resistance in Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2015; 59: 5267-5277.
12. Feuerriegel S, Schleusener V, Beckert P, et al. PhyResSE: a web tool delineating Mycobacterium tuberculosis antibiotic resistance and lineage from whole-genome sequencing data. J Clin Microbiol 2015; 53: 1908-1914.
13. Sandgren A, Strong M, Muthukrishnan P, Weiner B K, Church G M, Murray M B. Tuberculosis drug resistance mutation database. PLOS Med 2009; 6: e2.
14. Broad Institute. Tuberculosis Drug Resistance Mutation Database. Cambridge, MA, USA: Broad Institute, 2014. http://www.broadinstitute.org/annotation/genome/mtb-drug- resistance.1/DirectedSequencingHome.html. Accessed October 2017.
15. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. Tuberculosis surveillance and monitoring in Europe 2015. Stockholm, Sweden: ECDC, 2015.
16. Jenkins H E, Plesca V, Ciobanu A, et al. Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a highburden country. Eur Respir J 2013; 42: 1291-1301.
17. Skrahina A, Hurevich H, Zalutskaya A, et al. Alarming levels of drug-resistant tuberculosis in Belarus: results of a survey in Minsk. Eur Respir J 2012; 39: 1425-1431.
18. Skrahina A, Hurevich H, Zalutskaya A, et al. Multidrugresistant tuberculosis in Belarus: the size of the problem and associated risk factors. BullWorld Health Organ 2013; 91: 36-45.
19. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. WHO/HTM/TB/ 2016.04. Geneva, Switzerland: WHO, 2016.
20. Falzon D, Schünemann H J, Harausz E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J 2017; 49: 1 602 308.
21. Zignol M, Dean A S, Alikhanova N, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis 2016; 16: 1185-1192.
22. Murphy A, Levchuk N, Stickley A, Roberts B, McKee M. A country divided? Regional variation in mortality in Ukraine. Int J Public Health 2013; 58: 837-844.
23. Ulmasova D, Uzakova G, Tillyashayhov M, et al. Multidrugresistant tuberculosis in Uzbekistan: results of a nationwide survey, 2010 to 2011. Euro Surveill 2013; 18: 20609. http:// www.eurosurveillance.org/images/dynamic/EE/V18N42/ art20609.pdf. Accessed October 2017.
24. Mdivani N, Zangaladze E, Volkova N, et al. High Prevalence of multidrug-resistant tuberculosis in Georgia. Int J Infect Dis 2008; 12: 635-644.
25. van den Hof S, Tursynbayeva A, Abildaev T, et al. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan. Int J Tuberc Lung Dis 2013; 17: 526-531.